The Board declared a quarterly dividend of $0.125 per share, payable on January 3, 2025 to shareholders of record on December 12, 2024. The Board authorized the Company to repurchase up to 1,000,000 ...
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Åsa ...
HG202 is the first CRISPR/Cas13Y RNA-targeting therapy to enter clinical development and the only clinical-stage CRISPR RNA-editing therapy for age-related macular degeneration Preclinical studies in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback